Legal & General Group Plc boosted its stake in Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) by 8.5% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 28,205 shares of the biopharmaceutical company’s stock after purchasing an additional 2,220 shares during the period. Legal & General Group Plc’s holdings in Keryx Biopharmaceuticals were worth $203,000 at the end of the most recent quarter.
A number of other large investors also recently bought and sold shares of the business. Bank of New York Mellon Corp grew its position in Keryx Biopharmaceuticals by 3.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 963,054 shares of the biopharmaceutical company’s stock worth $6,963,000 after purchasing an additional 32,687 shares during the period. State of Wisconsin Investment Board bought a new stake in Keryx Biopharmaceuticals in the 2nd quarter worth approximately $441,000. Rhumbline Advisers grew its position in Keryx Biopharmaceuticals by 0.3% in the 2nd quarter. Rhumbline Advisers now owns 99,711 shares of the biopharmaceutical company’s stock worth $721,000 after purchasing an additional 335 shares during the period. Rice Hall James & Associates LLC grew its position in Keryx Biopharmaceuticals by 24.3% in the 2nd quarter. Rice Hall James & Associates LLC now owns 1,666,934 shares of the biopharmaceutical company’s stock worth $12,052,000 after purchasing an additional 326,285 shares during the period. Finally, Monarch Partners Asset Management LLC bought a new stake in Keryx Biopharmaceuticals in the 2nd quarter worth approximately $3,059,000. 65.19% of the stock is owned by institutional investors and hedge funds.
Shares of Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) opened at 7.13 on Friday. The stock’s 50 day moving average is $7.25 and its 200-day moving average is $6.74. The company’s market cap is $846.69 million. Keryx Biopharmaceuticals, Inc. has a 12 month low of $4.11 and a 12 month high of $8.38.
Keryx Biopharmaceuticals (NASDAQ:KERX) last released its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported ($0.77) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by ($0.60). The firm had revenue of $15.10 million for the quarter, compared to analyst estimates of $14.51 million. Keryx Biopharmaceuticals had a negative net margin of 431.89% and a negative return on equity of 2,902.87%. The firm’s quarterly revenue was up 62.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.42) EPS. On average, equities analysts forecast that Keryx Biopharmaceuticals, Inc. will post ($1.23) EPS for the current year.
A number of equities research analysts have commented on KERX shares. Zacks Investment Research downgraded shares of Keryx Biopharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, September 8th. Morgan Stanley reaffirmed an “equal weight” rating and issued a $7.00 target price (up previously from $4.00) on shares of Keryx Biopharmaceuticals in a research report on Tuesday, July 25th. BidaskClub downgraded shares of Keryx Biopharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, August 8th. ValuEngine raised shares of Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, August 1st. Finally, Maxim Group set a $9.00 target price on shares of Keryx Biopharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, July 27th. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and two have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $7.48.
Keryx Biopharmaceuticals Profile
Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.
Receive News & Ratings for Keryx Biopharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.